Stay updated on Olaparib Maintenance Retreatment in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Olaparib Maintenance Retreatment in Ovarian Cancer Clinical Trial page.

Latest updates to the Olaparib Maintenance Retreatment in Ovarian Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check20 days agoChange Detected- Updated the page to v3.2.0 and added a government-operational status notice clarifying potential delays and open status of NIH Clinical Center. - Removed the previous version tag v3.1.0.SummaryDifference2%

- Check27 days agoChange DetectedPage now shows Revision: v3.1.0 and removes several pharmaceutical topics (e.g., Drug Safety, Ovarian cancer, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs).SummaryDifference0.3%

- Check42 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2. The 'Back to Top' link was removed as a minor UI change.SummaryDifference0.1%

- Check49 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.1%

- Check56 days agoChange DetectedThe webpage has been updated to include a comprehensive list of facility names and locations related to ovarian cancer research, along with new publications from PubMed. Notably, the drug olaparib is highlighted in the context of its safety and use in treating malignant epithelial tumors of the ovary.SummaryDifference9%

- Check70 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%

Stay in the know with updates to Olaparib Maintenance Retreatment in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Olaparib Maintenance Retreatment in Ovarian Cancer Clinical Trial page.